SCHEMBL4013445

SCHEMBL4013445

CS(=O)(=O)c1ccccc1OS(=O)(=O)c1ccc2[nH]nc(-c3ccccc3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ TTK P33981 10/20 0.44
▸ DCLK1 O15075 1/20 0.44
▸ PRKD3 O94806 1/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ CHEK2 O96017 1/20 0.44
▸ CSF1R P07333 1/20 0.44
▸ FER P16591 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ MARK3 P27448 1/20 0.44
▸ FLT4 P35916 1/20 0.44
▸ FLT3 P36888 1/20 0.44
▸ MAPK9 P45984 1/20 0.44
▸ CSNK1D P48730 1/20 0.44
▸ CLK2 P49760 1/20 0.44
▸ CSNK2A1 P68400 1/20 0.44
▸ CSNK1G2 P78368 1/20 0.44
▸ MAP4K2 Q12851 1/20 0.44
▸ STK3 Q13188 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4008960 0.86 HSD11B1 (0.37) CSNK2A1PDPK1LRRK2ALDH1A1GAA
SCHEMBL4013510 0.85 HSD11B1 (0.41) CSNK2A1PDPK1KDM4EALDH1A1GAA
SCHEMBL4010520 0.85 HSD11B1 (0.36) CSNK2A1PDPK1ALDH1A1GAANTRK1
SCHEMBL4010492 0.85 HSD11B1 (0.36) CSNK2A1PDPK1LRRK2ALDH1A1GAA
SCHEMBL4010189 0.82 NTRK1 (0.39) TTKCSNK2A1NTRK3PDPK1LRRK2
SCHEMBL4007967 0.81 NTRK1 (0.41) MAPTMAP4K4CDK2MARK3CLK2
SCHEMBL4007930 0.80 TTK (0.56) HPGDMAPTTTKDCLK1PRKD3
SCHEMBL4009508 0.80 NTRK1 (0.51) MAP4K4CDK2MARK3FLT3CLK2
SCHEMBL4007991 0.79 CSNK2A1 (0.54) MAP4K4CDK2MARK3FLT3CLK2
SCHEMBL4008083 0.79 CDK7 (0.48) DCLK1PRKD3MAP4K4CHEK2FER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
EP-1487803-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY Aventis Pharma S.A. (FR) 2004-12-22 — — EP disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed
WO-2003078402-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY AVENTIS PHARMA S.A. (FR) 2003-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 HPGD 1246/4885MAPT 2426/4885TTK 215/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 HPGD 1303/4885MAPT 3070/4885TTK 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback